KRRO (Korro Bio) Beginning Cash Position: $25.23 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KRRO Korro Bio Inc KRRO
6 GF Score
Price $13.01
! 5 Warning Signs
View Full Analysis

What is Korro Bio Beginning Cash Position?

Korro Bio KRRO -1.81% 6 Beginning Cash Position is $25.23 Mil as of Mar. 2026. GuruFocus rates KRRO with a GF Score™ of 6/100. The stock has 5 warning signs investors should review.

Korro Bio's Beginning Cash Position for the quarter that ended in Mar. 2026 was $25.23 Mil.

Korro Bio's quarterly Beginning Cash Position declined from Sep. 2025 ($37.02 Mil) to Dec. 2025 ($27.56 Mil) and declined from Dec. 2025 ($27.56 Mil) to Mar. 2026 ($25.23 Mil).

Korro Bio's annual Beginning Cash Position increased from Dec. 2023 ($41.48 Mil) to Dec. 2024 ($173.12 Mil) but then declined from Dec. 2024 ($173.12 Mil) to Dec. 2025 ($59.05 Mil).

Korro Bio Beginning Cash Position Related Terms

Korro Bio Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Korro Bio's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Korro Bio Beginning Cash Position Chart

Korro Bio Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
39.69 84.04 41.48 173.12 59.05

Korro Bio Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 59.05 67.55 37.02 27.56 25.23
KRRO
6GF Score
Korro Bio Inc KRRO
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Korro Bio Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $25.23 Mil mean?
Korro Bio (KRRO) has a Beginning Cash Position of $25.23 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Korro Bio and its competitors.
Is Korro Bio's Beginning Cash Position too high?
Korro Bio's current Beginning Cash Position is $25.23 Mil. Overall, Korro Bio has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Korro Bio's Beginning Cash Position compare to LENZ and ANTX?
Korro Bio's Beginning Cash Position of $25.23 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Korro Bio and its competitors. Korro Bio's current Beginning Cash Position is $25.23 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Korro Bio stock overvalued right now?
Korro Bio (KRRO) has a current Beginning Cash Position of $25.23 Mil. The current Beginning Cash Position is $25.23 Mil. Korro Bio's overall GF Score™ is 6/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Korro Bio (KRRO), the current Beginning Cash Position is $25.23 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Korro Bio Business Description

Address 60 First Street, 2nd Floor, Suite 250, Cambridge, MA, USA, 02141
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.
6GF Score

Get the complete analysis for KRRO

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.01
Price